Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells
European Journal of Pharmaceutics and Biopharmaceutics · 2023
DOI: 10.1016/j.ejpb.2023.04.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Niloufar Rezaei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Departm…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nanoparticles. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Gastric cancer (GC) is known as a deadly malignancy all over the world, yet none of the current therapeutic regimens have achieved efficacy. this current study has aimed to optimize and reduce treatment doses and overcome multidrug resistance in GC by developing optimum niosomal formulation for the delivery of doxorubicin (DXR), paclitaxel (PTX), and their co-delivery. The particles' size, polydispersity index (PDI), and entrapment efficacy (EE%) were optimized using statistical techniques, i.e., Box-Behnken and Central Composite Design. In contrast to soluble drug formulations, the release rate of medicines from nanoparticles were higher in physiological and acidic pH. Niosomes were more stable at 4 °C, compared to 25 °C. The MTT assay revealed that the IC50 of drug-loaded niosomes was the lowest among all developed formulations. The apoptosis-related genes (CASPASE-3, CASPASE-8, and CASPASE-9) and tumor suppressor genes (BAX, BCL2) were evaluated in cancer cells before and after treatment. In comparison to control cells and cells treated with soluble forms of DXR and PTX, while the expression of BCL2 decreased, the expression of BAX, CASPASE-3, CASPASE-8, and CASPASE-9 was enhanced in cells treated with drug-loaded niosomes. Drug-loaded niosomes inhibited colony formation capacity and increased apoptosis in human AGS gastric cancer cells. Our results indicate that co-delivery of DXR and PTX-loaded niosomes may be an effective and innovative therapeutic approach to gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Department of Biotechnology, School of Chemical Engineering, College of Engin…
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: nikookhannazer@gmail.com.
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: ebimsv@sta…
Zitieren
APA
Rezaei, N., Kazem Arki, M., Miri-Lavasani, Z., Solhi, R., Khoramipour, M., Rashedi, H., Asadzadeh Aghdaei, H., Hossein-Khannazer, N., Mostafavi, E., & Vosough, M. (2023). Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.04.016
Vancouver
Rezaei N, Kazem Arki M, Miri-Lavasani Z, Solhi R, Khoramipour M, Rashedi H, et al. Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.04.016
BibTeX
@article{Rezaei2023,
author = {Rezaei, Niloufar and Kazem Arki, Mandana and Miri-Lavasani, Zohre and Solhi, Roya and Khoramipour, Mahsa and Rashedi, Hamid and Asadzadeh Aghdaei, Hamid and Hossein-Khannazer, Nikoo and Mostafavi, Ebrahim and Vosough, Massoud},
title = {Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
doi = {10.1016/j.ejpb.2023.04.016}
}
EUVIMED